Genetic hypercalciuric stone-forming rats

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 4, 2006, Pages 403-418

  Bushinsky, David A ^a   Frick, Kevin K ^a   Nehrke, Keith ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Calcium oxalate; Calcium phosphate; Idiopathic hypercalciuria; Nephrolithiasis; Vitamin D receptor

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM OXALATE; CALCIUM SENSING RECEPTOR; CHLORTALIDONE; CINACALCET; HYDROXYPROLINE; THIAZIDE DIURETIC AGENT; VITAMIN D RECEPTOR;

BONE; BREEDING; CALCIUM ABSORPTION; CALCIUM BONE LEVEL; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM OXALATE STONE; CALCIUM TRANSPORT; CALCIUM URINE LEVEL; GENE EXPRESSION; GENETIC DISORDER; GENETIC LINKAGE; HUMAN; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; INTESTINE; KIDNEY; KIDNEY TUBULE ABSORPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STONE FORMATION;

ADSORPTION; ANIMALS; CALCIUM OXALATE; CALCIUM, DIETARY; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; KIDNEY CALCULI; RATS; RATS, MUTANT STRAINS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 33748070185     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000232881.35469.a9     Document Type: Review

References (122)

1. Pak CY. Nephrolithiasis. Current Ther Endo Metab 1997; 6:572-576.
2. Bushinsky DA. Renal Lithiasis. In: Humes HD, editor. Kelly's Textbook of Medicine. New York: Lippincott Williams & Wilkins; 2000. pp. 1243-1248.
3. Bushinsky DA, Nephrolithiasis. J Am Soc Nephrol 1998; 9:917-924.
4. Monk RD, Bushinsky DA. Nephrolithiasis and nephrocalcinosis. In: Johnson R, Frehally J, editors. Comprehensive clinical nephrology, 2nd ed. London: Mosby; 2003. pp. 731-744.
5. Consensus Conference. Prevention and treatment of kidney stones. JAMA 1988; 260:977-981.
6. Pak CYC. Pathophysiology of calcium nephrolithiasis. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology, 2nd ed. New York: Raven Press; 1992. pp. 2461-2480.
7. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141-1152.
8. Asplin JR, Favus MJ, Coe FL. Nephrolithiasis. In: Brenner BM, editor. The kidney, 6th ed. Philadelphia: WB Saunders Company; 2000. pp. 1774-1819.
9. Monk RD, Bushinsky DA. Kidney stones. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology, 10th ed. Philadelphia: WB Saunders; 2003. pp. 1411-1425.
10. Bushinsky DA. Recurrent hypercalciuric nephrolithiasis - does diet help? N Eng J Med 2002; 346:124-125.
11. Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol Renal Fluid Electrolyte Physiol 1984; 247:F1-F13.
12. Parks JH, Coe FL. Pathogenesis and treatment of calcium stones. Semin Nephrol 1996; 16:398-411.
13. Bushinsky DA, Krieger NS. Integration of calcium metabolism in the adult. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism. New York: Raven Press; 1992. pp. 417-432.
14. Bushinsky DA, Krieger NS. Role of the skeleton in calcium homeostasis. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology, 2nd ed. New York: Raven Press; 1992. pp. 2395-2430.
15. Hodgkinson A, Pyrak LN. The urinary excretion of calcium and inorganic phosphate in 344 patients w/calcium stone of renal origin. Br J Surg 1958; 46:10-18.
16. Coe FL, Parks JH. Familial (idiopathic) hypercalciuria. In: Coe FL, Parks JH, editors. Nephrolithiasis: pathogenesis and treatment, 2nd ed. Chicago: Year Book Medical Publishers; 1990. pp. 108-138.
17. 3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982; 72:25-32.
18. Kim M, Sessler NE, Tembe V, et al. Response of genetic hypercalciuric rats to a low calcium diet. Kidney Int 1993; 43:189-196.
19. Bushinsky DA, Kim M, Sessler NE, et al. Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats. Kidney Int 1994; 45:58-65.
20. Li X-Q, Tembe V, Horwitz GM, et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats: a cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 91:661-667.
21. Favus MJ, Coe FL. Evidence for spontaneous hypercalciuria in the rat. Mineral Electrolyte Met 1979; 2:150-154.
22. Bushinsky DA, Favus MJ. Mechanism of hypercalciuria in genetic hypercalciuric rats: inherited defect in intestinal calcium transport. J Clin Invest 1988; 82:1585-1591.
23. Bushinsky DA, Favus MJ, Langman C, Coe FL. Mechanism of chronic hypercalciuria with furosemide: increased calcium absorption. Am J Physiol Renal Fluid Electrolyte Physiol 1986; 251:F17-F24.
24. Bushinsky DA, Favus MJ, Coe FL. Mechanism of chronic hypocalciuria with chlorthalidone: reduced calcium absorption. Am J Physiol Renal Fluid Electrolyte Physiol 1984; 247:F746-F752.
25. Bushinsky DA. Genetic hypercalciuric stone forming rats. Semin Nephrol 1996; 16:448-457.
26. Monk RD, Bushinsky DA. Pathogenesis of idiopathic hypercalciuria. In: Coe F, Favus M, Pak C, et al., editors. Kidney stones: medical and surgical management. Philadelphia: Lippincott-Raven; 1996. pp. 759-772.
27. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995; 98:50-59.
28. Robertson WG, Morgan DB. The distribution of urinary calcium excretion in normal persons and stone-formers. Clin Chim Acta 1972; 37:503-508.
29. Coe FL. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983; 24:392-403.
30. Maschio G, Tessitore N, D'Angelo A, et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. Am J Med 1981; 71:623-626.
31. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Int Med 1977; 87:404-410.
32. Coe FL, Parks JH, Nakagawa Y. Protein inhibitors of crystallization. Semin Nephrol 1991; 11:98-109.
33. Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2000; 57:550-560.
34. Bushinsky DA. Nephrolithiasis: site of the initial solid phase. J Clin Invest 2003; 111:602-605.
35. Birge SJ, Peck WA, Berman M, Whedon GD. Study of calcium absorption in man: a kinetic analysis and physiologic model. J Clin Invest 1969; 48:1705-1713.
36. Wills MR, Zisman E, Wortsman J, et al. The measurement of intestinal calcium absorption by external radioisotope counting: application to study of nephrolithiasis. Clin Sci 1970; 39:95-106.
37. Pak CYC, East DA, Sanzenbacher LJ, et al. Gastrointestinal calcium absorption in nephrolithiasis. J Clin Endocrinol Metab 1972; 35:261-270.
38. Pak CYC, Ohata M, Lawrence EC, Snyder W. The hypercalciurias: causes, parathyroid functions, and diagnostic criteria. J Clin Invest 1974; 54:387-400.
39. Kaplan RA, Haussler MR, Deftos LJ, et al. The role of 1,25 dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59:756-760.
40. Shen FH, Baylink DJ, Nielsen RL, et al. Increased serum 1,25-dihydroxy-vitamin D in idiopathic hypercalciuria. J Lab Clin Med 1977; 90:955-962.
41. Bushinsky DA. Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens 1999; 8:479-488.
42. Mehes K, Szelid Z. Autosomal dominant inheritance of hypercalciuria. Eur J Pediatr 1980; 133:239-242.
43. Harangi F, Mehes K. Family investigatons in idiopathic hypercalciuria. Eur J Pediatr 1993; 152:64-68.
44. Polito C, La Manna A, Cioce F, et al. Clinical presentation and natural course of idiopathic hypercalciuria in children. Pediatr Nephrol 2000; 15:211-214.
45. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979; 300:337-340.
46. Bushinsky DA, Asplin JR. Thiazides reduce brushite, but not calcium oxalate, supersaturation and stone formation in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol 2005; 16:417-424.
47. Asplin JR, Bushinsky DA, Singharetnam W, et al. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 1997; 51:640-645.
48. Bushinsky DA, Grynpas MD, Nilsson EL, et al. Stone formation in genetic hypercalciuric rats. Kidney Int 1995; 48:1705-1713.
49. Bushinsky DA, Asplin JR, Grynpas MD, et al. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2002; 61:975-987.
50. Karnauskas AJ, van Leeuwen JP, van den Bemd GJ, et al. Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Min Res 2005; 20:447-454. This study supports the hypothesis that prolongation of VDR half-life increases VDR tissue levels and mediates increased VDR-regulated gene expression that result in hypercalciuria through actions on vitamin D-regulated calcium transport in intestine, bone, and kidney.
51. 3 in bone from genetic hypercalciuric rats. Am J Physiol Cell Physiol 1996; 271:C130-C135.
52. Bushinsky DA, Bashir MA, Riordon DR, et al. Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int 1999; 55:602-612.
53. Tsuruoka S, Bushinsky DA, Schwartz GJ. Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997; 51:1540-1547.
54. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999; 55:234-243.
55. 3: a new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest 1998; 101:2223-2232.
56. Evan AP, Bledsoe SB, Smith SB, Bushinsky DA. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 2004; 65:154-161.
57. Scheinman SJ, Cox JPD, Lloyd SE, et al. Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int 2000; 57:232-239.
58. Bushinsky DA, Grynpas MD, Asplin JR. Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone forming rats. Kidney Int 2001; 59:1415-1423.
59. Bushinsky DA, LaPlante K, Asplin JR. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int 2006 (in press).
60. Hoopes RR, Reid R, Sen S, et al. Quantitative trait loci for hypercalciuria in a rat model of kidney stone disease. J Am Soc Nephrol 2003; 14:1844-1850.
61. Bushinsky DA. Bench to bedside: lessons from the genetic hypercalciuric stone forming rat. Am J Kidney Dis 2000; 36:61-64.
62. Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Neph 2003; 14:1082-1095.
63. Lemann F J Jr. Pathogenesis of idiopathic hypercalciuria and nephrolithiasis. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism. New York: Raven Press; 1992. pp. 685-706.
64. Henneman PH, Benedict PH, Forbes AP, Dudley HR. Idiopathic hypercalciuria. N Engl J Med 1958; 259:802-807.
65. Jackson WPU, Dancaster C. A consideration of the hypercalciuria in sarcoidosis, idiopathic hypercalciuria, and that produced by vitamin D. A new suggestion regarding calcium metabolism. J Clin Endocrinol Metab 1959; 19:658-681.
66. Edwards NA, Hodgkinson A. Metabolic studies in patients with idiopathic hypercalciuria. Clin Sci 1965; 29:143-157.
67. Liberman UA, Sperling O, Atsmon A, et al. Metabolic and calcium kinetic studies in idiopathic hypercalciuria. J Clin Invest 1968; 47:2580-2590.
68. Harrison AR. Some results of metabolic investigation in cases of renal stone. Br J Urol 1959; 31:398-403.
69. Dent CE, Harper CM, Parfitt AM. The effect of cellulose phosphate on calcium metabolism in patients with hypercalciuria. Clin Sci 1964; 27:417-425.
70. Nassim JR, Higgins BA. Control of idiopathic hypercalciuria. Br Med J 1965; 1:675-681.
71. 45Ca in stone-forming patients. Br Med J 1965; 1:427-429.
72. Ehrig U, Harrison JE, Wilson DR. Effect of long-term thiazide therapy on intestinal calcium absorption in patients with recurrent renal calculi. Metabolism 1974; 23:139-149.
73. Barilla DE, Tolentino R, Kaplan RA, Pak CYC. Selective effects of thiazide on intestinal absorption of calcium in absorptive and renal hypercalciurias. Metabolism 1978; 27:125-131.
74. Zerwekh JE, Pak CYC. Selective effect of thiazide therapy on serum 1, 25-dihydroxyvitamin D, and intestinal absorption in renal and absorptive hypercalciuria. Metabolism 1980; 29:13-17.
75. Broadus AE, Dominguez M, Bartter FC. Pathophysiological studies in idiopathic hypercalciuria: use of an oral calcium tolerance test to characterize distinctive hypercalciuric subgroups. J Clin Endocrinol Metab 1978; 47:751-760.
76. Bataille P, Bouillion R, Fournier A, et al. Increased plasma concentrations of total and free 1,25(OH)2D3 in calcium stone formers with idiopathic hypercalciuria. Contr Nephrol 1987; 58:137-142.
77. Duncombe VM, Watts RWE, Peters TJ. Studies on intestinal calcium absorption in patients with idiopathic hypercalciuria. Q J Med 1984; 209:69-79.
78. Broadus AE, Insogna KL, Lang R, et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311:73-80.
79. Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193-1205.
80. 3) in patients with idiopathic hypercalciuria (IH). Clin Res 1975; 23:423A.
81. 3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol Metab 1976; 5:151S-165S.
82. 2 vitamin D levels in humans: studies in healthy subjects, in calcium stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1977; 45:299-306.
83. Broadus AE, Insoqna KL, Lang R. A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J Clin Endocrinol Metab 1984; 58:161-169.
84. Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 1973; 52:134-142.
85. Bordier P, Ryckewart A, Gueris J, Rasmussen H. On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med 1977; 63:398-409.
86. Insogna KL, Broadus AE, Dryer BE, et al. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 1985; 61:490-495.
87. Barkin J, Wilson DR, Manuel MA, et al. Bone mineral content in idiopathic calcium nephrolithiasis. Min Electro Metab 1985; 11:19-24.
88. Pietschmann F, Breslau NA, Pak CYC. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7:1383-1388.
89. Lawoyin S, Sismilich S, Browne R, Pak CYC. Bone mineral content in patients with calcium urolithiasis. Metabolism 1979; 28:1250-1254.
90. Alhava EM, Juuti M, Karjalainen P. Bone mineral density in patients with urolithiasis. Scand J Urol Nephrol 1976; 10:154-156.
91. Malluche H, Tschoepe W, Ritz E, et al. Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980; 50:654-658.
92. Maierhofer WJ, Lemann F J Jr, Gray RW, Cheung HS. Dietary calcium and serum 1,25(OH)2-vitamin D concentration as determinants of calcium balance in healthy men. Kidney Int 1984; 26:752-759.
93. 3 concentrations in healthy men. Kidney Int 1983; 24:555-560.
94. Pak CYC, McGuire J, Peterson R, et al. Familial absorptive hypercalciuria in a large kindred. J Urol 1981; 126:717-719.
95. Tanaka H, Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem Mol Biol 2004; 89-90:343-345.
96. Sooy K, Sabbagh K, Demay MB. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J Cell Biochem 2005; 94:81-87.
97. Hoenderop JGJ, Bindels RJM. Epithelial Ca2+ and Mg2+ channels in health and disease. J Am Soc Nephrol 2005; 16:15-26.
98. Favus MJ. Hypercalciuria: lessons from studies of genetic hypercalciuric rats. J Am Soc Nephrol 1994; 5:S54-S58.
99. Pols HAP, Birkenhager JC, Schilte JP, Visser TJ. Evidence that self-induced metabolism of 1,25-dihydroxyvitamin D3 limits the homologous up-regulation of its receptor in rat osteosarcoma cells. Biochim Biophys Acta 1988; 970:122-129.
100. Reinhardt TA, Horst RL. Self-induction of 1,25-dihydroxyvitamin D3 metabolism limits receptor occupancy and target tissue responsiveness. J Biol Chem 1989; 264:15917-15921.
101. Favus MJ, Mangelsdorf DJ, Tembe V, et al. Evidence for in vivo upregulation of the intestinal vitamin D receptor during dietary calcium restriction in the rat. J Clin Invest 1988; 82:218-224.
102. Strom M, Sandgren ME, Brown TA, DeLuca HF. 1,25-Dihydroxyvitamin D3 up-regulated the 1,25 dihydroxyvitamin D3 receptor in vivo. Proc Natl Acad Sci USA 1989; 86:9770-9773.
103. Sandgren M, DeLuca HF. Serum calcium and vitamin D regulate 1,25-dihydroxyvitamin D3 receptor concentration in rat kidney in vivo. Proc Natl Acad Sci USA 1990; 87:4312-4314.
104. 3 and dexamethasone on rat osteoblast-like cell cultures: receptor occupancy and functional expression patterns for three different bioresponses. Endocrinology 1986; 118:250-259.
105. 3 receptors by analogs in cultured mammalian cells. Endocrinology 1985; 117:2203-2210.
106. Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89:4937-4943.
107. Riccardi D, Park J, Lee WS, et al. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 1995; 92:131-135.
108. Goodman WG. Calcium-sensing receptors. Semin Nephrol 2004; 23:17-24.
109. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81:239-297.
110. Canaff L, Hendy GN. Human calclium-sensing receptor gene Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277:30337-30350.
111. 3 in genetic hypercalciuric stone forming rats. J Am Soc Nephrol 2005; 16:1300-1308. The GHS rats were found to have high levels of CaR gene expression and CaR protein that may contribute to hypercalciuria and calcium nephrolithiasis.
112. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Neph 2003; 14:575-583.
113. Drueke TB. Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 2004; 19:20-26.
114. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Eng J Med 2004; 350:1516-1525.
115. Coe FL, Parks JH. New insights into the pathophysiology and treatment of nephrolithiasis: New research venues. J Bone Miner Res 1997; 12:522-533.
116. Evan AP, Lingeman JE, Coe FL, et al. Randall plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111:607-616.
117. Carr RJ. A new theory on the formation of renal calculi. Br J Urol 1953; 26:105-117.
118. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003; 278:22144-22152.
119. Fischer JW, Steitz SA, Johnson PY, et al. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24:2391-2396.
120. Rosen CJ. Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 2004; 18:423-435.
121. Rosen CJ, Ackert-Bicknell C, Beamer WG, et al. Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. Pediatr Nephrol 2005; 20:255-260.
122. Kasukawa Y, Baylink DJ, Wergedall JE, et al. Lack of insulin-like growth factor I exaggerates the effect of calcium deficiency on bone accretion in mice. Endocrinology 2003; 144:4682-4689.